As aforementioned, PI3K/mTOR signaling is hyperactive in CML, and investigation of potential synergy between MTIs and TKIs targeting mutant ABL1 (e.g., imatinib, dasatinib) in CML is planned (NCT01188889) (39). This evidence concerns the gene MTOR and chronic myelogenous leukemia, BCR-ABL1 positive.